Methods of treating thyroid eye disease
The present invention relates to a methods and compositions for the treatment of and management of symptoms for thyroid eye disease. The methods include administering to a patient having thyroid eye disease an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space. The pharmaceutical compositions that includes a carrier suitable for ophthalmic delivery and an agent that interferes with hyaluronan synthesis. Combination therapies are also disclosed.
1. A method of treating thyroid eye disease comprising:
selecting a patient having thyroid eye disease and
administering to the selected patient a composition comprising an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space, wherein the agent is 4-benzhydryloxy-1-[3-(1H-tetrazol-5-yl)-propyl]-piperidine (HQL-79), ethyl 3-(2-(3-fluorophenyl)pyrimidine-5-carboxamido)pyrrolidine-1-carboxylate, N-(1-(7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)pyrrolidin-3-yl)-2-(3-fluorophenyl)pyrimidine-5-carboxamide, 2-(3-fluorophenyl)-N-{1-[(methylamino)carbonyl]piperidin-4-yl}pyrimidine-5-carboxamide, 2-(3-fluorophenyl)-N-[1-(6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)pyrrolidin-3-yl]pyrimidine-5-carboxamide, or 2-(3-fluorophenyl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyrimidine-5-carboxamide.
2. The method according to claim 1 , wherein the composition comprises a PPARγ ligand, wherein the PPARγ ligand is 15-deoxy-Δ12,14-Prostaglandin J2 or a thiazolidinedione.
3. The method according to claim 1 , wherein said administering is carried out by injecting the agent into the retro-ocular space or application of a composition comprising the agent onto a surface of the patient's eye.
4. The method according to claim 1 , wherein the composition is a pharmaceutical composition further comprising a carrier selected from the group consisting of a liquid, suspension, polymeric delivery vehicle, mucoadhesive substance, and nanosphere.
5. The method according to claim 1 , wherein the agent that interferes with hyaluronan synthesis is 4-benzhydryloxy-1-[3-(1H-tetrazol-5-yl)-propyl]-piperidine (HQL-79).